Clinical trial

Tolerance and Efficacy of Rituximab in Sjogren's Disease

NCT00740948

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Rituximab (mabthera) Injection Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo: NaCl 0.9% or Glucose 5% Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Tolerance and Efficacy of Rituximab in Sjogren's Disease

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2, PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2008-03-01

PhasePHASE2 / PHASE3

Conditions

Sjogren's Diseaseunresolved

Interventions

Rituximab (mabthera) InjectionDRUG

Placebo: NaCl 0.9% or Glucose 5%DRUG

Sponsors & collaborators

University Hospital, Brestlead sponsor

Ministry of Health, Francecollaborator

Mapped research locations

ParisFrance2 MarseilleFrance1 MontpellierFrance1 StrasbourgFrance1 LilleFrance1 NantesFrance1 RennesFrance1 Clermont-FerrandFrance1 RouenFrance1 BrestFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00740948 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.